Organigram finalizes acquisition of Sanity Group to secure European market leadership

Organigram Global (NASDAQ:OGI) announced today the successful closing of its acquisition of Sanity Group, a leading German cannabis company.

The transaction, originally outlined in a February 2026 agreement, marks a transformative step in Organigram’s international expansion strategy, positioning the company as a dominant player in the rapidly evolving European medical and adult-use cannabis markets.

The total upfront purchase price for the shares not previously owned by Organigram was €107.3 million.

This consideration was comprised of €78 million in cash and €29.3 million in Organigram share consideration.

To fund the cash portion of the deal and provide ongoing working capital, Organigram also finalized a private placement with BT DE Investments, a subsidiary of British American Tobacco (BAT).

The private placement generated gross proceeds of €40.3 million (approximately C$65.2 million).

Furthermore, the company closed on senior secured credit facilities totaling up to C$60 million to ensure a robust liquidity profile post-acquisition.